Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area.
Dutton JW, Chen H, You C, Brodie MS, Lasek AW.
Addict Biol · research-article; journal article · DOI 10.1111/adb.12358 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för alectinib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
21 träffarAlectinib Approved for ALK+ Lung Cancer.
Författaruppgift saknas
Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2016-001Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.
Fujita S, Masago K, Katakami N, Yatabe Y.
J Thorac Oncol · journal article; case reports · DOI 10.1016/j.jtho.2015.12.105ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Sullivan I, Planchard D.
Ther Adv Med Oncol · review-article; review; journal article · DOI 10.1177/1758834015617355Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, Ohgino K, Miyawaki M, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-15-0084Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).
Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Harada M, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T.
Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1093/annonc/mdv501ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.
Lung Cancer · journal article; case reports · DOI 10.1016/j.lungcan.2015.09.006Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Wong KM, Noonan S, O'Bryant C, Jimeno A.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2015.51.3.2294597I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.
Lung Cancer · journal article; case reports · DOI 10.1016/j.lungcan.2015.02.005Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT.
J Thorac Oncol · research-article; journal article; case reports; research support, n.i.h., extramural · DOI 10.1097/jto.0000000000000455Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
Koizumi T, Fukushima T, Tatai T, Kobayashi T, Sekiguchi N, Sakamoto A, Sasaki S.
Lung Cancer · journal article; case reports · DOI 10.1016/j.lungcan.2015.01.018Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance.
Song Z, Wang M, Zhang A.
Acta Pharm Sin B · review-article; review; journal article · DOI 10.1016/j.apsb.2014.12.007Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
Ajimizu H, Kim YH, Mishima M.
Med Oncol · journal article; case reports · DOI 10.1007/s12032-014-0477-7Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K.
Drugs · review; journal article · DOI 10.1007/s40265-014-0329-yActivated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.
Int J Oncol · research support, non-u.s. gov't; journal article · DOI 10.3892/ijo.2014.2797Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Ikeda S, Yoshioka H, Arita M, Sakai T, Sone N, Nishiyama A, Niwa T, Hotta M, Tanaka T, Ishida T.
Jpn J Clin Oncol · research support, non-u.s. gov't; journal article; case reports · DOI 10.1093/jjco/hyu183Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H.
Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-14-0274Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.
Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-14-1511Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H.
Cancer Chemother Pharmacol · journal article · DOI 10.1007/s00280-014-2578-6Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H.
Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2014.05.020Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
Ignatius Ou SH, Azada M, Hsiang DJ, Herman JM, Kain TS, Siwak-Tapp C, Casey C, He J, Ali SM, Klempner SJ, Miller VA.
J Thorac Oncol · journal article; case reports · DOI 10.1097/jto.0000000000000094